VIGENERON
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.
VIGENERON
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Starnberg, Bayern, Germany
Country:
Germany
Website Url:
http://www.vigeneron.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress Organization Schema Sitelinks Search Box JQuery CDN
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Celergen USA
Celergen USA is a health care cell therapy company.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Exegenesis Bio
Exegenesis Bio is a Gene therapy start-up.
Pronec
Pronec is a start-up cancer therapy company.
Smartemis
SMARTEMIS is a group of clinics at the service of the veterinary company.
Tailored Therapeutics
Tailored Therapeutics is a cell therapy company.
Current Employees Featured
Founder
Investors List
WuXi AppTec
WuXi AppTec investment in Series A - ViGeneron
Sequoia Capital China
Sequoia Capital China investment in Series A - ViGeneron
Official Site Inspections
http://www.vigeneron.com Semrush global rank: 5.66 M Semrush visits lastest month: 1.26 K
- Host name: dd37510.kasserver.com
- IP address: 85.13.154.24
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "ViGeneron"
VeonGen - The next generation gene therapy companyVeonGen
A next generation gene therapy company. At VeonGen Therapeutics (formerly ViGeneron), we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high …See details»
ViGeneron - The next generation gene therapy companyViGeneron
ViGeneron GmbH Semmelweisstraße 3 82152 Planegg. phone: +49 (0)89 6931489 00 fax: +49 (0)89 6931489 53. [email protected]. A next generation gene therapy company. At …See details»
ViGeneron - Crunchbase Company Profile & Funding
ViGeneron has 3 investors including Huagai Capital and WuXi AppTec. When was the last funding round for ViGeneron? ViGeneron closed its last funding round on Dec 23, 2024 from a Series A round. Who are ViGeneron 's …See details»
ViGeneron - AboutViGeneron
Caroline Man Xu has extensive experience leading global and regional cross-functional teams including 10 years at Novartis where she had global responsibilities for new products in the …See details»
ViGeneron - The Org
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in …See details»
VeonGen Therapeutics GmbH - LinkedIn
VeonGen Therapeutics GmbH | 1,136 followers on LinkedIn. Dedicated to develop the medicines of the future | ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians …See details»
ViGeneron - Overview, News & Competitors | ZoomInfo.com
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in …See details»
ViGeneron Company Profile - Office Locations, Competitors ... - Craft
ViGeneron has 1 employees across 2 locations. See insights on ViGeneron including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
ViGeneron Rebrands as VeonGen Therapeutics and Announces …
5 days ago ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt …See details»
VeonGen - News & EventsVeonGen - ViGeneron
ViGeneron, a gene therapy company, and WuXi Advanced Therapies, a contract, testing, development, and manufacturing organization (CTDMO), entered into a strategic partnership …See details»
ViGeneron Rebrands as VeonGen Therapeutics - VeonGen …
1 hour ago VeonGen also announced that its lead program VG801 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for the …See details»
ViGeneron Rebrands as VeonGen Therapeutics, Advancing Clinical …
4 days ago Gene therapy developer ViGeneron has rebranded as VeonGen Therapeutics, marking its evolution into a clinical-stage company with two gene therapies now in human …See details»
ViGeneron - ImprintViGeneron
ViGeneron GmbH. Semmelweisstraße 3 82152 Planegg. phone: +49 (0)89 6931489 00 fax: +49 (0)89 6931489 53 e-mail: [email protected]. Responsible for the content : Dr. Man Xu – …See details»
ViGeneron Rebrands as VeonGen Therapeutics and Announces …
4 days ago MUNICH, Germany I June 05, 2025 I VeonGen Therapeutics, formerly known as ViGeneron, today announced its rebranding to reflect its evolution into a clinical-stage genetic …See details»
ViGeneron Announces Closing of Series A Financing to Drive …
ViGeneron is a spin-off of the Ludwig-Maximilians-University (LMU) in Munich. The company’s founding team includes highly experienced executives and internationally renowned experts …See details»
ViGeneron - Funding, Financials, Valuation & Investors - Crunchbase
Dec 23, 2024 ViGeneron is a gene therapy company. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. ... How much funding has this organization …See details»
ViGeneron - ViGeneron and WuXi Advanced Therapies enter …
December 1, 2020 – Philadelphia, PA and Munich, Germany – ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, …See details»
ViGeneron - The next generation gene therapy companyViGeneron
A next generation gene therapy company At VeonGen, we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need. Our three novel …See details»
ViGeneron rebrands as VeonGen Therapeutics, announces rare …
5 days ago ViGeneron rebrands as VeonGen Therapeutics and announces FDA Rare Pediatric Disease Designation and clinical progress for lead gene therapy VG801 in Stargardt Disease. …See details»
ViGeneron - EU-Startups
ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At ViGeneron we are dedicated to develop innovative gene therapies based on our two unique …See details»